 |
0 Diseases |  |
12 Trials |
|
12 Trials |  |
1320 News |  |
| «12...345678910111213...2223» |
- | hyoscine butylbromide oral / Generic mfg.
Journal: Anticholinergic Toxicity in the Emergency Department. (Pubmed Central) - Jul 19, 2023
1-4 Plants that possess anticholinergic properties such as jimson weed, and street drugs cut with anticholinergics such as scopolamine are sources of accidental or intentional ingestion.1,2,4 Anticholinergic toxicity can cause a myriad of signs and symptoms, including agitation, seizures, hyperthermia, cardiac dysrhythmias, and death...It was found to be effective when debriefing sessions using various debriefing techniques (such as advocacy/inquiry) were utilized to discuss both the learners' performance in the case, as well as the debriefing pearls (located at the end of this manuscript). Anticholinergic toxicity, altered mental status, toxicology.
- | hyoscine butylbromide oral / Generic mfg.
Journal: Invest?gat?on of the protect?ve effect of long-term exerc?se on molecular pathways and behav?ours ?n scopolam?ne ?nduced alzhe?mer's d?sease-l?ke cond?t?on. (Pubmed Central) - Jul 17, 2023
In conclusion, long-term exercise may have a protective effect against scopolamine-induced impairments in cognitive-emotional behaviour. It can be suggested that this protective effect is mediated by increased BDNF levels and GSK3
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Polyphenol-enriched Desmodium elegans DC. ameliorate scopolamine-induced amnesia in animal model of Alzheimer's disease: In Vitro, In Vivo and In Silico approaches. (Pubmed Central) - Jul 12, 2023
It can be suggested that this protective effect is mediated by increased BDNF levels and GSK3 A total of 16 compounds were identified which include gallic acid (239
- | RSL3 / Stanford University
Journal, IO biomarker: Design, synthesis and biological evaluation of new multi-target scutellarein hybrids for treatment of Alzheimer's disease. (Pubmed Central) - Jul 10, 2023
Notably, 11e significantly reduced ?-amyloid precursor protein (APP) and ?-site APP cleaving enzyme-1 (BACE-1) protein expression in brain tissue of scopolamine-treated mice. Taken together, these outstanding properties qualified compound 11e as a promising multi-target candidate for AD therapy, worthy of further studies.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Standardized extract of Glehnia Littoralis abrogates memory impairment and neuroinflammation by regulation of CREB/BDNF and NF-?B/MAPK signaling in scopolamine-induced amnesic mice model. (Pubmed Central) - Jul 8, 2023
Furthermore, GLE treatment attenuated the increased phosphorylation of NF-?B/MAPK signaling in the hippocampus and cortex. These results suggest that GLE has a potential neuroprotective activity that may ameliorate learning and memory impairment by regulating AChE activity, promoting CREB/BDNF signaling, and inhibiting NF-?B/MAPK signaling and neuroinflammation.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Folicitin abrogates scopolamine induced oxidative stress, hyperlipidemia mediated neuronal synapse and memory dysfunction in mice. (Pubmed Central) - Jul 7, 2023
All these results revealed that folicitin being a potent anti-oxidant is capable of improving synaptic dysfunction and reducing oxidative stress through Nrf-2/HO-1 pathway, thus plays a key role in treating Alzheimer disease as well as possess hyperglycemic and hyperlipidemic effect. Furthermore, a detailed study is suggested.
- SUVN-I6107 / Suven Life Sci
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7308;
SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects
- hyoscine butylbromide oral / Generic mfg.
"Unraveling the Neuroprotective Mechanism of Dioscorea bulbifera (DB) in Alzheimer's Disease (AD) Caused by Estrogen Loss: An Integrated Network Pharmacology Investigation and Experimental Validation" (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7040;
Our findings provide experimental support for the predicted mechanism of action of DB in AD caused by estrogen loss, and validate its neuroprotective effects using behavioral tests and ELISA in ovariectomized rats. DB may hold promise as a potential therapeutic option for AD, particularly in the context of estrogen loss, and further research is warranted to explore its full potential in AD treatment.
- hyoscine butylbromide oral / Generic mfg.
Natural trimethoxyflavone improves memory in mice via cholinergic, oxidative, inflammatory and apoptotic pathways (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6110;
These results suggest that DHF was effective in treating scopolamine induced cognitive deficit by improving cerebral cholinergic dysfunction and reducing brain oxidative stress, inflammation, apoptosis and beta-amyloid depositions in mice. Thus, DHF could be developed as a potential alternative drug to treat memory disorders.
- SUVN-I6107 / Suven Life Sci
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5242;
SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects
- hyoscine butylbromide oral / Generic mfg.
"Unraveling the Neuroprotective Mechanism of Dioscorea bulbifera (DB) in Alzheimer's Disease (AD) Caused by Estrogen Loss: An Integrated Network Pharmacology Investigation and Experimental Validation" (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_4973;
Our findings provide experimental support for the predicted mechanism of action of DB in AD caused by estrogen loss, and validate its neuroprotective effects using behavioral tests and ELISA in ovariectomized rats. DB may hold promise as a potential therapeutic option for AD, particularly in the context of estrogen loss, and further research is warranted to explore its full potential in AD treatment.
- SUVN-I6107 / Suven Life Sci
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2996;
SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects
- hyoscine butylbromide oral / Generic mfg.
"Unraveling the Neuroprotective Mechanism of Dioscorea bulbifera (DB) in Alzheimer's Disease (AD) Caused by Estrogen Loss: An Integrated Network Pharmacology Investigation and Experimental Validation" (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2728;
Our findings provide experimental support for the predicted mechanism of action of DB in AD caused by estrogen loss, and validate its neuroprotective effects using behavioral tests and ELISA in ovariectomized rats. DB may hold promise as a potential therapeutic option for AD, particularly in the context of estrogen loss, and further research is warranted to explore its full potential in AD treatment.
- hyoscine butylbromide oral / Generic mfg.
Cholinergic deficit induced memory retrieval deficit and hippocampal CaMKII-alpha deregulation is counteracted by sub-chronic agmatine treatment in mice (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1892;
might play a role in scopolamine induced amnesia and sub-chronic agmatine prevents the impairing effect of scopolamine on the retrieval phase of memory and the phosphorylation of hippocampal CaMKII-? protein.
- hyoscine butylbromide oral / Generic mfg.
POORANA CHANDROTHAYA CHENTHURAM (PCC), A SIDDHA SYSTEM OF MEDICINE PROTECTS AGAINST SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENTS IN EXPERIMENTAL RATS (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1709;
These results suggest that the PCC ameliorates scopolamine-induced impairment of cognitive functions in rats. These data further support that the anti-amnestic effect of PCC recommends it as a promising candidate for clinical trials in patients with cognitive impairment.
- hyoscine butylbromide oral / Generic mfg.
Dihydroxytrimethoxyflavone possess memory improvement effects against scopolamine in mice via modulating multiple pathways: In-silico and in-vivo evidences (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1708;
These results suggest that DHF was effective in treating scopolamine induced cognitive deficit by improving cerebral cholinergic dysfunction and reducing brain oxidative stress, inflammation, apoptosis and beta-amyloid depositions in mice. Thus, DHF could be developed as a potential alternative drug to treat memory disorders.
- SUVN-I6107 / Suven Life Sci
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_776;
SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects
- hyoscine butylbromide oral / Generic mfg.
"Unraveling the Neuroprotective Mechanism of Dioscorea bulbifera (DB) in Alzheimer's Disease (AD) Caused by Estrogen Loss: An Integrated Network Pharmacology Investigation and Experimental Validation" (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_509;
Our findings provide experimental support for the predicted mechanism of action of DB in AD caused by estrogen loss, and validate its neuroprotective effects using behavioral tests and ELISA in ovariectomized rats. DB may hold promise as a potential therapeutic option for AD, particularly in the context of estrogen loss, and further research is warranted to explore its full potential in AD treatment.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Hesperetin attenuates cognitive dysfunction via SIRT6/NLRP3 pathway in scopolamine-induced mice. (Pubmed Central) - Jun 29, 2023
Meanwhile, hesperetin could attenuate the expression of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), thioredoxin-interacting protein (TXNIP), and caspase-1 p20 and upregulate the expression of SIRT6 in SCOP-induced mice. Overall, our study suggested that hesperetin might ameliorate SCOP-induced cognitive dysfunction by improving cholinergic system dysfunction and suppressing oxidative stress and attenuating neuroinflammation via SIRT6/NLRP3 pathway in mice.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Synergistic Effect of Combined Walnut Peptide and Ginseng Extracts on Memory Improvement in C57BL/6 Mice and Potential Mechanism Exploration. (Pubmed Central) - Jun 28, 2023
This work aimed to investigate whether there are synergistic effects between walnut peptide (WNP) and ginseng extracts (GSE) treatments to ameliorate the memory impairment caused by scopolamine (SCOP)...In addition, compared with the model group, WNP + GSE significantly enhanced the protein levels of VAChT, Trx-1, and the CREB/BDNF/TrkB pathway in hippocampal and PC12 cells induced by SCOP (p < 0.05). Notably, WNP + GSE boosted memory via multiple pathways, not only the BDNF/TrkB/CREB target.
- | hyoscine butylbromide oral / Generic mfg.
Journal: Extraction, isolation, synthesis, and biological evaluation of novel piperic acid derivatives for the treatment of Alzheimer's disease. (Pubmed Central) - Jun 23, 2023
Moreover, 6j could effectively reverse scopolamine-induced amnesia by improving spatial and cognitive memory in mice. The above results strongly suggest that compound 6j may act as a novel multi-targeted lead for AD therapy.
- || hyoscine butylbromide oral / Generic mfg.
Cyanide. Hyoscine. Atropine. (Twitter) - Jun 22, 2023
- | hyoscine butylbromide oral / Generic mfg., celecoxib oral / Generic mfg.
New trial: How to Reduce Pain in Patients Undergoing Office Hysteroscopy. (clinicaltrials.gov) - Jun 19, 2023
P=N/A, N=180, Not yet recruiting, Sponsor: Cairo University
- | Miostat (carbachol) / Novartis
Preclinical, Journal: Hypokinetic Activity of Menthofuran on the Gastrointestinal Tract in Rodents. (Pubmed Central) - Jun 19, 2023
Interestingly, a scopolamine-similar hypokinetic effect was observed for menthofuran. Additionally, menthofuran induced a marked concentration-dependent relaxation in rat ileum segments precontracted with KCl (EC?=?0.059?
- | hyoscine butylbromide oral / Generic mfg., donepezil / Generic mfg.
Preclinical, Journal: Memory Enhancing and Neurogenesis Activity of Honey Bee Venom in the Symptoms of Amnesia: Using Rats with Amnesia-like Alzheimer's Disease as a Model. (Pubmed Central) - Jun 16, 2023
Conclusively, BV has a potential nootropic and therapeutic activity that enhances hippocampal growth and plasticity, which in turn improves WM and LTM. Given that this research was conducted using scopolamine-induced amnesia-like AD in rats, it suggests that BV has a potential therapeutic activity for the enhancement of memory in AD patients in a dose-dependent manner but further investigations are needed.
- | imipramine / Generic mfg., hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Zanthoxylum Alatum Attenuates Chronic Restraint Stress Adverse Behavioral Effects Via the Mitigation of Oxidative Stress and Modulating the Expression of Genes Involved in Endoplasmic Reticulum Stress in Mice. (Pubmed Central) - Jun 15, 2023
Based on traditional medicine and our previous studies on Zanthoxylum alatum in lipopolysaccharide-induced depressive behavior and scopolamine-induced impaired memory, the present study explored the role of hydroalcoholic extract of Z. alatum (ZAHA) seeds in reducing the ER stress in mice...ZAHA (100 and 200 mg/kg, PO) and imipramine (10 mg/kg, IP) were administered daily, 45 min before restraint from day 22 to 28...Hesperidin, magnoflorine, melicopine, and sesamin, isolated from the active extract, were hypothesized to exert the activity. It can be concluded that Z. alatum reverted chronic restraint stress through its antioxidant properties and down-regulation of genes involved in ER stress.
- | hyoscine butylbromide oral / Generic mfg., donepezil / Generic mfg., rivastigmine / Generic mfg.
Journal: Design, Synthesis, and Biological Evaluation of Piperazine and N-Benzylpiperidine Hybrids of 5-Phenyl-1,3,4-oxadiazol-2-thiol as Potential Multitargeted Ligands for Alzheimer's Disease Therapy. (Pubmed Central) - Jun 8, 2023
levels, which was comparable to donepezil-treated group. Compounds 5d and 5f represent new lead candidates for developing AD therapeutics.
- | hyoscine butylbromide oral / Generic mfg.
Journal: Pro-neurogenic effects of Lilii Bulbus on hippocampal neurogenesis and memory. (Pubmed Central) - Jun 2, 2023
Compounds 5d and 5f represent new lead candidates for developing AD therapeutics. WELB (50 and 100
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Zinc Ortho Methyl Carbonodithioate Improved Pre and Post-Synapse Memory Impairment via SIRT1/p-JNK Pathway against Scopolamine in Adult Mice. (Pubmed Central) - Jun 1, 2023
The predicted interaction of ZOMEC with SIRT1 was further confirmed by molecular docking. These findings thus provide initial reports on efficacy of ZOMEC in SCOP induced AD model.
- || Akineton (biperiden) / Endo, AbbVie
Retrospective data, Review, Journal: Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. (Pubmed Central) - Jun 1, 2023
There was a high RoB in our included study, especially in terms of dealing with possible cofounders. The limitations of this study suggest a need for more well-designed studies with a longer duration of follow-up on this topic to reach more reliable evidence.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Umbelliferone Ameliorates Memory Impairment and Enhances Hippocampal Synaptic Plasticity in Scopolamine-Induced Rat Model. (Pubmed Central) - May 31, 2023
These cognitive improvements were in association with the enhanced expression of BDNF, TrkB, and the pCREB/CREB ratio and the suppression of acetylcholinesterase activity. The current findings indicate that UMB may be an effective neuroprotective reagent applicable for improving learning and memory against AD.
- | hyoscine butylbromide oral / Generic mfg.
Journal: 8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases. (Pubmed Central) - May 30, 2023
The current findings indicate that UMB may be an effective neuroprotective reagent applicable for improving learning and memory against AD. In addition, in
- Zolgensma (onasemnogene abeparvovec-xioi) / Novartis
Onasemnogene aboparvovec in children with SMA: Outcome and experience from a single centre in the United Arab Emirates (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_830;
Our experience shows that Onasemnogene abeparvovec is well tolerated, and the transient side effects can be minimized with a higher dose of steroids. Improvements in the motor skills are notable with improved respiratory outcomes.
- | hyoscine butylbromide oral / Generic mfg.
Journal: The central administration of vitisin a, extracted from Vitis vinifera, improves cognitive function and related signaling pathways in a scopolamine-induced dementia model. (Pubmed Central) - May 29, 2023
Further studies showed that vitisin A upregulates BDNF-CREB signaling in the hippocampus. Together, our findings suggest that vitisin A exhibits neuroprotective effects, at least partially, by upregulating BDNF-CREB signaling and LTP.
- | hyoscine butylbromide oral / Generic mfg., donepezil / Generic mfg.
Preclinical, Journal: Design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone-based derivatives as promising acetylcholinesterase inhibitors for treatment of Alzheimer's disease. (Pubmed Central) - May 27, 2023
The kinetic analysis for compound 17c suggested this compound as a mixed-type inhibitor that could bind to both the peripheral (PAS) and the catalytic site (CAS) of the hAChE enzyme. The synthesized molecules were subjected to in silico analyses, including molecular docking studies, and the outcomes were consistent with the in vitro findings.
- | hyoscine butylbromide oral / Generic mfg., memantine / Generic mfg.
Preclinical, Journal: Effect of Curcumin and Coenzyme Q10 Alone and in Combination on Learning and Memory in an Animal Model of Alzheimer's Disease. (Pubmed Central) - May 27, 2023
These outcomes are comparable to those of the common medication memantine. As a result, we may infer from our results that curcumin at higher doses and its combination with coenzyme Q10 (200 mg/kg b.w. p.o.) have a significant impact on cognitive impairment in animal models of Alzheimer's disease and can be utilised alone or as an add-on therapy for the condition.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Lignan-Rich Sesame (Sesamum indicum L.) Cultivar Exhibits In Vitro Anti-Cholinesterase Activity, Anti-Neurotoxicity in Amyloid-? Induced SH-SY5Y Cells, and Produces an In Vivo Nootropic Effect in Scopolamine-Induced Memory Impaired Mice. (Pubmed Central) - May 27, 2023
Pretreatment with the M74 extract (250 and 500 mg/kg) and oil (1 and 2 mL/kg) effectively improved memory disorder in mice (demonstrated by the passive avoidance test), inhibited AChE, and enhanced acetylcholine (Ach) levels. Moreover, immunohistochemistry and Western blot results showed that the M74 extract and oil reversed the scopolamine-induced increase in APP, BACE-1, and presenilin expression levels in the amyloid cascade and decreased BDNF and NGF expression levels in neuronal regeneration.
- | hyoscine butylbromide oral / Generic mfg.
Journal: The Effect of Ethanol Extract from Mesua ferrea Linn Flower on Alzheimer's Disease and Its Underlying Mechanism. (Pubmed Central) - May 26, 2023
aggregation, and neuroprotection against oxidative stress and A?. Therefore, the M. ferrea L. flower might be a possibility for further development as a medication for AD.
- | hyoscine butylbromide oral / Generic mfg.
Journal: The Vestibular Time Constant and Clinical Response to Antimotion Sickness Medication. (Pubmed Central) - May 24, 2023
Reduction in the vestibular time constant after scopolamine administration can be used to predict whether motion sickness alleviation will occur. This will enable the administration of appropriate pharmaceutical treatment without the need for prior exposure to sea conditions.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Lantana camara leaf extract ameliorates memory deficit and the neuroinflammation associated with scopolamine-induced Alzheimer's-like cognitive impairment in zebrafish and mice. (Pubmed Central) - May 22, 2023
This will enable the administration of appropriate pharmaceutical treatment without the need for prior exposure to sea conditions. Zebrafish (AB strain) and mice (ICR) were given donepezil (0.65?mg/kg, oral) and LCE (10, 30, 100?mg/kg, oral) for 7, and 10?days, respectively, before induction of cognitive impairment with scopolamine immersion (200?
- | hyoscine butylbromide oral / Generic mfg.
Journal: Anti-oomycete ability of scopolamine against Phytophthora infestans, a terrible pathogen of potato late blight. (Pubmed Central) - May 20, 2023
To our knowledge, this is the first study to detect scopolamine inhibitory activity against P. infestans. Also, our findings highlight the potential of scopolamine as an eco-friendly option for controlling late blight in the future.
- | hyoscine butylbromide oral / Generic mfg.
Journal: Insights into the Hippocampus Proteomics Reveal Epigenetic Properties of Walnut-Derived Peptides in a Low-Grade Neuroinflammation Model. (Pubmed Central) - May 19, 2023
The enriched KEGG pathways included oxidative phosphorylation, riboflavin metabolism, ribosome, and pyrimidine metabolism, which are associated with methylation modification by oral administration of YVLLPSPK in mice with scopolamine-induced cognitive deficits...The results indicated that YVLLPSPK modulated DNA methylation in embryonic and neural precursor cells in creating new methylation patterns. Further trials are needed to assess the mechanisms underlying DNA methylation changes through peptides in the pathophysiology of neurological disorders.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Recycling of hyoscyamine 6?-hydroxylase for the in vitro production of anisodamine and scopolamine. (Pubmed Central) - May 15, 2023
- || hyoscine butylbromide oral / Generic mfg.
Clinical, Retrospective data: Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis. (Pubmed Central) - May 8, 2023
There were no significant associations of age, gender, education, or age of onset with the two trajectory groups. Scopolamine added to antidepressants can effectively relieve the symptoms of patients with severe depression, and it decreases faster than patients with moderate depression.
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Author Correction: Anti-amnesic and anti-cholinesterase activities of ?-asarone against scopolamine-induced memory impairments in rats. (Pubmed Central) - May 4, 2023
The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/29660.
- | hyoscine butylbromide oral / Generic mfg., pilocarpine / Generic mfg.
Journal: Immobilization of M3 Muscarinic Receptor to Rapidly Analyze Drug-Protein Interactions and Bioactive Components in a Natural Plant. (Pubmed Central) - May 2, 2023
https://www.europeanreview.org/article/29660. The association constants of (-)-scopolamine hydrochloride, atropine sulfate, and pilocarpine to M3R were determined to be (2.39
- | hyoscine butylbromide oral / Generic mfg.
Journal: Polygoni Multiflori Radix Praeparata and Acori Tatarinowii Rhizoma ameliorate scopolamine-induced cognitive impairment by regulating the cholinergic and synaptic associated proteins. (Pubmed Central) - May 1, 2023
The association constants of (-)-scopolamine hydrochloride, atropine sulfate, and pilocarpine to M3R were determined to be (2.39 These findings demonstrate that both of PA and P
- | hyoscine butylbromide oral / Generic mfg.
Journal: LC-MS/MS Approach for Simultaneous Assessment of Hyoscine N-butyl bromide and Ketoprofen in biological fluids and Pharmaceuticals. (Pubmed Central) - Apr 19, 2023
These findings demonstrate that both of PA and P The mean extraction recoveries for HBB and KTP were respectively, 91.04 and 97.83 % in spasmofen
- | hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Celastrus paniculatus oil ameliorates NF-KB mediated neuroinflammation and synaptic plasticity in the scopolamine-induced cognitive impairment rat model. (Pubmed Central) - Apr 19, 2023
It also restores synaptic plasticity. It thus improves cognitive functions against scopolamine-induced amnesia in rats by improving cholinergic function.
- | hyoscine butylbromide oral / Generic mfg.
Journal, Stroma: MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF-?B pathway. (Pubmed Central) - Mar 30, 2023
It thus improves cognitive functions against scopolamine-induced amnesia in rats by improving cholinergic function. hucMSCs-EVs alleviate DED signs, suppress inflammation and restore homeostasis of the corneal surface by multitargeting the IRAK1/TAB2/NF-?B pathway via certain miRNAs.